PRF Technologies (PRFX) Intangibles (2025)
PRF Technologies (PRFX) posted quarterly Intangibles of $7.4 million for Q4 2025, up 4.02% on a QoQ basis from $7.1 million in Q2 2025.
PRF Technologies (PRFX) Intangibles (2025) Analysis & Trends
PRF Technologies (PRFX) has reported Intangibles for 1 consecutive years, with $7.4 million the latest figure, recorded in Q4 2025.
- Quarterly Intangibles changed N/A year-over-year to $7.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.4 million (changed N/A YoY) and the FY2025 annual result came in at $7.4 million, changed N/A from the prior year.
- Intangibles advanced to $7.4 million in Q4 2025 per PRFX's latest filing, from $7.1 million in the prior quarter.
- Over the last five years, Intangibles for PRFX reached as high as $7.4 million in Q4 2025 and fell as low as $7.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 34.07 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.61 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 959.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 21.80 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 473.93 Mn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 14.48 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.23 Bn |
| 10 | PRF Technologies | 745,168.93 | 451,168.93 | - | 7.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.41 Mn |
| Jun 30, 2025 | 7.12 Mn |